| Document |
Document Title |
|
JP2006519255A |
Methods for the preparation of the 19-norprogesterone of formula I and its intermediates, in crystalline and amorphous forms.
|
|
JP3814284B2 |
This invention relates to processes for the preparation of 7-carboxy substituted steroid compounds of Formula I,
|
|
JP3807509B2 |
R-epimer enrichment of 16,17-acetal derivatives of 21-acyloxy pregna-1,4-dien-11beta,16alpha,17alpha-triol-3,20-dione derivatives is effected by fractional crystallization.
|
|
JP2002511415A5 |
|
|
JP2006151994A |
To provide a simple method for converting a pregnane-3,20-dione compound into a 3α-hydroxy-3β-substituted-pregnane.An unprotected dione is chemoselectively and stereoselelctively converted into a 3(R)-pregnane-3-spiro-2'-oxiran-20-one ...
|
|
JP2006515581A |
Process for the preparation of polyhalogenated steroids, in particular of androstanic fluoro derivatives corticosteroids by means of the formation of new androstanic S-hydroxy alkyl or aralkyl-17-carbothioate intermediates.
|
|
JP3768100B2 |
The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are als...
|
|
JP2006511483A |
2'' oxo-voruscharin compound and derivatives thereof are disclosed as well as pharmaceutical compositions which include 2'' oxo-voruscharin compound or derivatives thereof. The disclosed 2'' oxo-voruscharin compound and its derivatives a...
|
|
JP2006508963A |
Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selectiv...
|
|
JP2006056877A |
To relate to a method for producing steroid compounds and provide a new method for producing steroid compounds.Sterols bearing double bonds on the 5 position and the 24 position; for example, cholesta-5,7,24-triene-3β-ol, or ergosta-5,7...
|
|
JP2006052141A |
To treat diseases caused by a stress-based reduction of a function effectively by reinforcing reduced corticotropin-releasing factor (CRF or adrenocorticotropic hormone-releasing factor) activities, since the stress-based reduction of th...
|
|
JP3746075B2 |
Gonadal and D-homo gonadal steroid derivatives of formula (I) and their salts are new. A double bond may be present between atoms 9 and 11, 8 and 9, 8 and 14, 14 and 15, 6 and 7 or 7 and 8; between atoms 8 and 9 and 14 and 15 or between ...
|
|
JP2005502671T5 |
|
|
JP3734090B2 |
PCT No. PCT/EP95/00836 Sec. 371 Date Nov. 25, 1996 Sec. 102(e) Date Nov. 25, 1996 PCT Filed Mar. 7, 1995 PCT Pub. No. WO95/24416 PCT Pub. Date Sep. 14, 1995The invention describes a process for the epimer enrichment of compounds of formu...
|
|
JP2003502270A5 |
|
|
JP3727353B2 |
A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (I) or a salt thereof: wherein R<1> represen...
|
|
JP2005537256A |
The present invention is directed to novel estrieno[3,2-b]/[3,4-c]pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
|
|
JP3717511B2 |
Saponin/antigen conjugates and the use thereof for enhancing immune responses in individuals are disclosed. The saponins may be substantially pure or mixtures of saponins.
|
|
JP3710470B2 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
JP2005530679A |
A method for producing a 6α-fluorinated corticosteroid or derivative thereof by reacting a 17-hydroxy-21-ester epoxide of Formula II with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6α-fluorinat...
|
|
JP2005281315A |
To obtain an aqueous composition containing a medicine effective on the treatment of an abnormal physical state by the existence of the composition on the surface of a mucous membrane which covers a nasal cavity.This aqueous medicine com...
|
|
JP2005263742A |
To provide a medicine for enhancing the intrauterine appearance of integrin α5β1.There are provided an integrin α5β1 intrauterine appearance enhancer containing danazol as the effective component and a therapeutic agent containing da...
|
|
JP2005528365A |
The invention relates to novel 19-nor-17 alpha -pregna-1,3,5(10)-trien-17 beta -ols with a 21,16a lactone ring having a long-chain substituent in the 11 beta position of general formula (II), wherein R<11> represents a long-chain alkyl r...
|
|
JP2005528371A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP2005527496A |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long-acting ² 2 -adrenoreceptor agonis...
|
|
JP2005239551A |
To provide a drug or a food and drink effective for prophylaxis/treatment of arteriosclerosis by utilizing a biological regulating functions possessed by cycloartane type triterpene saponins found in Cimicifuga racemosa because it is nec...
|
|
JP2005524680A |
The process for the preparation of 6alpha-fluoro steroids, comprising the reaction of the corresponding 6beta-fluoro steroids, or of 6alpha/6beta isomeric mixtures with an organic base having a diazo iminic group, in a suitably selected ...
|
|
JP2005523927A |
The present invention relates to improved methods for synthesising cyproterone acetate (17 alpha -Acetoxy-6-chloro-1 alpha , 2 alpha -methylene-4,6-pregnadiene-3,20-dione) from solasodine. The methods of the invention are shorter as thos...
|
|
JP2005213216A |
To obtain an agent for relieving stress, derived from a natural product and safe after being administered for a long period by searching for a plant extract which is expected to achieve the recovery from the influence of the stress, and ...
|
|
JP2005523306A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP2005519925A |
A pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of formula (I) or a solv...
|
|
JP2005519913A |
The invention provides novel compounds that are quaternary amine derivatives of betulin and other triterpenes. The compounds have antibacterial, antifungal, and surfactant properties.
|
|
JP2005519852A |
The present invention relates to pharmaceutical compositions and methods of using such compositions for the treatment of inflammatory diseases of the bone and joints. The compositions comprise a catalyst for the dismutation of superoxide...
|
|
JP2005145948A |
To obtain an apoptosis-inducing agent capable of inducing cell death in cancerous cells specifically.This apoptosis-inducing agent which is an adjusting agent for an intracellular signal transmission system and an antitumor agent, is pro...
|
|
JP2005516015A |
The present invention provides methods for the treatment or prophylaxis of one or more aldosterone-mediated pathogenic effects in a subject suffering from or susceptible to the pathogenic effect or effects wherein the subject has one or ...
|
|
JP2005508345A |
The present invention relates to an improved extraction process for an alkaloid glycoside extract from the species Solanum. In this process, a ground, dried plant tissue of the species Solanum is subjected to alcohol extraction using met...
|
|
JP2005508281A |
A compound of formula (1): wherein each of R1, R2, R4, R4', R7, R11, R12, R15, R16, R17, and R17', independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted wit...
|
|
JP2005505578A |
The present invention is a process for the preparation of rofleponide of formula (II)where the 22R/22S ratio is 90/10 or greater which comprises contacting an acetonide of formula (I)with CH3-CH2-CH2-CHO (III) in the presence of perchlor...
|
|
JP2004538294A |
6 alpha -fluorpregnanes (I), where the dotted line between positions 1 and 2 represents a single or double bond; R1 is OH, OCOR2, X, SO3R3, or an (R7)(R8)(R9)SiO- group, where X is halogen, R2 and R3 are C1-6 alkyl or phenyl optionally s...
|
|
JP2004536802A |
The present invention relation to a pharmaceutical composition comprising chelidonine or derivatives thereof, with pharmaceutically acceptable carriers. The compositions according to the present invention can selectively block hKv1.5 cha...
|
|
JP2004535441A |
A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1alpha,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxi...
|
|
JP3587933B2 |
|
|
JP3576927B2 |
Carbonate derivatives (I) of retinol are new. Carbonate derivatives of retinol of formula (I) are new: R = 1-18C, linear, branched or cyclic, saturated or unsaturated hydrocarbyl, optionally substituted by one or more of hydroxy, OR', NH...
|
|
JP2004528296A |
The present invention relates to methods for the synthesis of chemical compounds for screening as potential tubulin polymerization inhibitors. The invention also provides chemical compounds with tubulin polymerization inhibitor activity.
|
|
JP2004527519A |
The invention relates to a novel compound oleanane triterpenoid oligoglycoside of formula 1 of the accompanying drawing (trivially called corniculatonin), the invention also relates to a process for the isolation of the novel compound fr...
|
|
JP2004525945A |
The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the ab...
|
|
JP2004224797A |
To provide a medicament having no side effect but high activity and for treatment of conditions characterized by deficiency in postsynaptic membrane-bound receptor number or function.The treatment of cognitive disfunction and similar con...
|
|
JP3553086B2 |
A pharmaceutical composition contains an extract obtainable from a plant of the genus Trichocaulon or Hoodia containing an appetite suppressant agent having the formula (1). A process for obtaining the extract and a process for synthesiz...
|
|
JP2004217666A |
To obtain a highly active steroid sapogenin and its derivatives for treatment of cognitive dysfunction and analogous conditions without inducing cholinergic adverse effects such as fatigue, diarrhea and nausea.The subject medicine for tr...
|
|
JP2004518611A |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed
|
